Compare · ILMN vs YDES
ILMN vs YDES
Side-by-side comparison of Illumina Inc. (ILMN) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $29.37B, about 185.1x YDES ($158.7M).
- Over the past year, ILMN is up 77.5% and YDES is down 83.1% - ILMN leads by 160.7 points.
- ILMN has been more active in the news (5 items in the past 4 weeks vs 4 for YDES).
- ILMN has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Illumina Inc.
- YD Bio Limited
- Price
- $194.06-1.49%
- $2.25-1.96%
- Market cap
- $29.37B
- $158.7M
- 1M return
- +10.86%
- -14.91%
- 1Y return
- +77.55%
- -83.12%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest YDES
- YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
- YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
- Director Lu Shao-Ta converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
- Director Chang Kochi converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
- SEC Form EFFECT filed by YD Bio Limited
- SEC Form POS AM filed by YD Bio Limited
- YD Bio Limited Reports Full Year 2025 Financial Results
- SEC Form 20-F filed by YD Bio Limited
- Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 4 filed by Lu Shao-Ta